25
total announcements
AJANTPHARM.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 21 Oct 2026
Market Cap
₹41,234 Cr
P/E (TTM)
40.7
P/E (Forward)
33.2
EPS (TTM)
₹81.11
52W Low
₹2,022.05
52W High
₹3,390.05
Dividend Yield
1.98%
Beta
0.16
Price / Book
9.6
Debt / Equity
5.7
Revenue (TTM)
₹5,202 Cr
Gross Margin
76.27%
Operating Margin
24.64%
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced its Q1 FY 2027 results, with revenue up 25% and PAT up 31% YoY. The company has also declared an interim dividend of Rs. 32 per share, amounting to Rs. 400 cr. The company's India branded generic segment has exceeded IPM growth by 36%, driven by new launches and volumes.
Ajanta Pharma Ltd
Ajanta Pharma Ltd reported a 25% increase in revenue and 31% increase in PAT for Q1 FY 2027, with a dividend of Rs. 32 per share declared.
Ajanta Pharma Ltd
Ajanta Pharma Ltd reported Q1 FY 2027 results, with revenue up 25% and PAT up 31% YoY. The company declared an interim dividend of Rs. 32 per share, amounting to Rs. 400 cr. The company's India branded generic segment exceeded IPM growth by 36%.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has made a disclosure under SEBI (SAST) Regulations, 2011, regarding a substantial acquisition of shares by Aayush Agrawal, trustee, on July 29, 2026.
Ajanta Pharma Ltd
Ajanta Pharma Ltd has announced a revised timing for its earnings conference call scheduled to be held on July 30, 2026, after the board meeting. The call will now take place at 4:15 p.m. IST, and the company will release its Q1 FY 2027 unaudited financial results on the same day at 4:15 p.m. IST.